 Metformin
"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
| Descriptor ID |
D008687
|
| MeSH Number(s) |
D02.078.370.141.450
|
| Concept/Terms |
Metformin- Metformin
- Dimethylbiguanidine
- Dimethylguanylguanidine
|
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in this website by year, and whether "Metformin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 1 | 3 | | 2005 | 2 | 3 | 5 | | 2006 | 1 | 2 | 3 | | 2007 | 3 | 4 | 7 | | 2008 | 3 | 3 | 6 | | 2009 | 6 | 3 | 9 | | 2010 | 1 | 3 | 4 | | 2011 | 3 | 1 | 4 | | 2012 | 5 | 5 | 10 | | 2013 | 4 | 2 | 6 | | 2014 | 5 | 5 | 10 | | 2015 | 8 | 3 | 11 | | 2016 | 5 | 3 | 8 | | 2017 | 10 | 6 | 16 | | 2018 | 12 | 4 | 16 | | 2019 | 6 | 6 | 12 | | 2020 | 10 | 3 | 13 | | 2021 | 17 | 6 | 23 | | 2022 | 9 | 2 | 11 | | 2023 | 14 | 1 | 15 | | 2024 | 13 | 1 | 14 | | 2025 | 7 | 5 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Knowler WC, Pan Q, Shu S, Tripputi MT, Dabelea D, Edelstein SL, Kahn SE, Kuo S, Luchsinger JA, Shah V, Wallia A, Temprosa M. Analysis of Long-term Follow-up of a Randomized Clinical Trial With Departures From Assigned Treatments: Estimation of Metformin Effects on Diabetes and Its Complications in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2025 Oct 01; 48(10):1668-1675.
-
Bramante CT, Stewart TG, Boulware DR, McCarthy MW, Gao Y, Rothman RL, Mourad A, Thicklin F, Cohen JB, Garcia Del Sol IT, Ruiz-Unger J, Shah NS, Mehta M, Cardona OQ, Scott J, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, Collins S, Dunsmore SE, Adam SJ, Lindsell CJ, Hernandez AF, Naggie S. Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial. JAMA Intern Med. 2025 Sep 01; 185(9):1092-1101.
-
Presley CA, Butera NM, Krause-Steinrauf H, Desouza CV, Hollander PA, Hoogendoorn CJ, Lagari VS, Legowski EA, Martin CL, Rasouli N, Gonzalez JS, Cherrington AL. Lack of Association of Emotional Distress With Insulin Initiation in the GRADE Randomized Diabetes Comparative Effectiveness Trial. Sci Diabetes Self Manag Care. 2025 Aug; 51(4):382-393.
-
Heckman-Stoddard BM, Crandall JP, Edelstein SL, Prorok PC, Dabelea D, Hamman R, Hazuda HP, Horton E, Hoskin MA, Perloff M, Bowers A, Knowler WC, Ford LG, Temprosa M. Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program. Cancer Prev Res (Phila). 2025 Jul 01; 18(7):401-411.
-
Crandall JP, Dabelea D, Knowler WC, Nathan DM, Temprosa M. The Diabetes Prevention Program and Its Outcomes Study: NIDDK's Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact. Diabetes Care. 2025 Jul 01; 48(7):1101-1111.
-
Massengill D, Abou Nader MF, Good R, Sam Wang G. Persistent Biventricular Cardiac Dysfunction Following a Large, Acute Metformin Overdose. Pediatrics. 2025 Jun 01; 155(6).
-
van Baar MJB, Muskiet MHA, Scholtes RA, Touw DJ, Nieuwdorp M, Kramer MHH, Joles JA, Cherney DZI, Bjornstad P, Krebber MM, van Raalte DH. Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial. Diabetes Obes Metab. 2025 Jul; 27(7):3943-3956.
-
Knowler WC, Doherty L, Edelstein SL, Bennett PH, Dabelea D, Hoskin M, Kahn SE, Kalyani RR, Kim C, Pi-Sunyer FX, Raghavan S, Shah VO, Temprosa M, Venditti EM, Nathan DM. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. Lancet Diabetes Endocrinol. 2025 Jun; 13(6):469-481.
-
Hosseini M, Voisin V, Chegini A, Varesi A, Cathelin S, Ayyathan DM, Liu ACH, Yang Y, Wang V, Maher A, Grignano E, Reisz JA, D'Alessandro A, Young K, Wu Y, Fiumara M, Ferrari S, Naldini L, Gaiti F, Pai S, Egan G, Schimmer AD, Bader GD, Dick JE, Xie SZ, Trowbridge JJ, Chan SM. Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs. Nature. 2025 Jun; 642(8067):421-430.
-
Utzschneider KM, Tripputi M, Butera NM, Mari A, Rosin SP, Banerji MA, Bergenstal RM, Brown N, Carlson AL, DeFronzo RA, Gramzinski MR, Harindhanavudhi T, Kozedub A, Sivitz WI, Steffes MW, Balasubramanyam A, Rasouli N. Differential Treatment Effects on ß-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2025 Apr 01; 48(4):623-631.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|